Thermo Fisher Launches Global CorEvitas Alzheimer’s Registry With First Patient Enrolled, Advances Real-World Evidence In Alzheimers

Thermo Fisher Scientific has announced the enrollment of the first patient in its newly launched PPD™ CorEvitas™ Alzheimer’s Disease Registry, marking a major step toward generating high-quality global real-world evidence in Alzheimer’s disease. The registry is designed as an international, multi-country initiative operating under a unified global protocol to deliver harmonized, regulator-ready data on the safety and effectiveness of Alzheimer’s therapies.

Built as a longitudinal registry, the initiative will collect clinician-reported data from routine clinical practice, enabling a comprehensive assessment of treatment outcomes in real-world settings. The registry aims to improve understanding of long-term safety profiles, treatment patterns, and the evolving use of approved therapies, while also helping to identify unmet medical needs and clarify the real-life impact of Alzheimer’s disease on patients and caregivers.

A key focus of the registry is detailed safety monitoring, including MRI-based evaluations of brain swelling and bleeding associated with certain Alzheimer’s treatments, as well as assessments of amyloid plaque clearance, an important marker linked to cognitive outcomes. These data will support more informed evaluations of benefit–risk profiles and clinical effectiveness across diverse patient populations.

“The launch of this registry reflects the power of collaboration between clinicians, industry partners and scientific leaders to accelerate progress in Alzheimer’s disease research,” said Peter Wahl, Sc.D, vice president and global head of scientific affairs for PPD CorEvitas Clinical Registries, Thermo Fisher Scientific. “Together, we are building a regulatory-grade, real-world evidence foundation that will help shape the understanding of current and next generation of therapies.”

Alzheimer’s disease remains a major public health challenge, affecting an estimated 7.2 million Americans aged 65 and older, a figure projected to double by 2050. As one of the leading causes of death in the U.S., the disease underscores the urgent need for robust, real-world evidence to guide therapeutic development, regulatory decision-making, and patient care. While there is currently no cure or means of prevention, available treatments may help manage symptoms and potentially slow disease progression.

The Alzheimer’s Disease Registry further expands Thermo Fisher’s PPD™ CorEvitas™ Clinical Registries portfolio, which includes proprietary disease registries spanning more than 500 investigator sites and over 100,000 patients worldwide. These registries are widely used to support post-authorization safety studies and have been recognized by regulatory authorities globally for their scientific rigor and real-world relevance.